Department of Internal Medicine, Grigore T. Popa University of Medicine and Pharmacy, 700115 Iasi, Romania.
Internal Medicine Clinic, St. Spiridon County Clinical Emergency Hospital Iasi, 700111 Iasi, Romania.
Cells. 2022 Aug 27;11(17):2663. doi: 10.3390/cells11172663.
Calcific aortic valve disease (CAVD) is a major cause of cardiovascular mortality and morbidity, with increased prevalence and incidence. The underlying mechanisms behind CAVD are complex, and are mainly illustrated by inflammation, mechanical stress (which induces prolonged aortic valve endothelial dysfunction), increased oxidative stress (OS) (which trigger fibrosis), and calcification of valve leaflets. To date, besides aortic valve replacement, there are no specific pharmacological treatments for CAVD. In this review, we describe the mechanisms behind aortic valvular disease, the involvement of OS as a fundamental element in disease progression with predilection in AS, and its two most frequent etiologies (calcific aortic valve disease and bicuspid aortic valve); moreover, we highlight the potential of OS as a future therapeutic target.
钙化性主动脉瓣疾病(CAVD)是心血管死亡率和发病率的主要原因,其患病率和发病率都有所增加。CAVD 的潜在机制很复杂,主要包括炎症、机械应力(导致主动脉瓣内皮功能障碍延长)、氧化应激增加(OS)(触发纤维化)和瓣叶钙化。迄今为止,除了主动脉瓣置换术外,针对 CAVD 还没有特定的药物治疗方法。在这篇综述中,我们描述了主动脉瓣疾病背后的机制,OS 作为疾病进展中的一个基本因素的参与,以及其两种最常见的病因(钙化性主动脉瓣疾病和二叶式主动脉瓣);此外,我们还强调了 OS 作为未来治疗靶点的潜力。